EUCTR2021-005020-38-ES进行中(未招募)1 期
A randomized, double-blind, placebo-controlled, Phase III trial to evaluate the efficacy and safety of a single intra-articular injection of RTX-GRT7039 in adult subjects with pain associated with osteoarthritis of the knee.
试验速览
- 阶段
- 1 期
- 状态
- 进行中(未招募)
- 入组人数
- 450
研究概览
简要总结
暂无简介。
研究设计
- 研究类型
- Interventional clinical trial of medicinal product
入排标准
- 性别
- All
入选标准
- •= 18 years of age at the screening visit.
- •Body Mass Index (BMI) = 40.0 kg/m2.
- •Diagnosis of osteoarthritis of the knee based on American College of Rheumatology criteria and functional capacity class of I-III.
- •Moderate to severe osteoarthritis at baseline.
- •Documented history indicating that subject has insufficient pain relief with optimal standard of care (SoC).
- •The investigator does not consider that any additional benefit can reasonably be expected from further adjustments to the patient’s pain treatment.
- •Are the trial subjects under 18? no
- •Number of subjects for this age range:
- •F.1.2 Adults (18-64 years) yes
- •F.1.2.1 Number of subjects for this age range 180
- •F.1.3 Elderly (>=65 years) yes
- •F.1.3.1 Number of subjects for this age range 270
排除标准
- •The subject had an intra-articular injection of either corticosteroid or intra-articular visco-supplementation (i.e., hyaluronic acid) into the index knee within 3 months.
- •The subject had an injection of platelet-rich plasma into the index knee within 6 months.
- •The subject applied topical capsaicin on the index knee within 3 months.
- •Pre-existing rapidly progressing osteoarthritis (RPOA) Type I or Type II, osteonecrosis, subchondral insufficiency fracture, atrophic osteoarthritis, or the subject has knee pain attributable to disease other than osteoarthritis.
- •Other conditions that could confound discrimination of pain assessment in the index knee.
- •Clinically significant disease(s) or condition(s) that may affect efficacy or safety assessments, or any other reason which, in the investigator's opinion, may preclude the subject's participation in the full duration of the trial.
- •History of severe allergic or anaphylactic reactions.
- •History of significant trauma or surgery, or surgery planned during the trial period, related to the knee.
研究者
相似试验
进行中(未招募)
不适用
A randomized, double-blind, placebo-controlled, Phase III trial of 2 regimens of telaprevir (with and without delayed start) combined with pegylated interferon alfa-2a (Pegasys®) and ribavirin (Copegus®) in subjects with chronic genotype 1 hepatitis C infection who failed prior pegylated interferon plus ribavirin treatment. - REALIZEEUCTR2008-000533-22-ATTibotec BVBA650
已完成
3 期
A randomized, double-blind, placebo-controlled, Phase III trial of 2 regimens of telaprevir (with and without delayed start) combined with pegylated interferon alfa-2a (Pegasys®) and ribavirin (Copegus®) in subjects with chronic genotype 1 hepatitis C infection who failed prior pegylated interferon plus ribavirin treatment.NL-OMON32876Janssen-Cilag18
进行中(未招募)
不适用
A randomized, double-blind, placebo-controlled, Phase III trial of 2 regimens of telaprevir (with and without delayed start) combined with pegylated interferon alfa-2a (Pegasys) and ribavirin (Copegus) in subjects with chronic genotype 1 hepatitis C infection who failed prior pegylated interferon plus ribavirin treatment - NDEUCTR2008-000533-22-ITTIBOTEC BVBA650
招募中
2 期
A clinical study evaluating efficacy and safety of inupadenant in combination with carboplatin and pemetrexed in adults with metastatic nonsquamous non-small cell lung cancer who have progressed on immunotherapy2024-515393-27-00iTeos Belgium131
进行中(未招募)
不适用
A randomized, double-blind, placebo-controlled, Phase 2b study of LY2409021 in patients with type 2 diabetes mellitus - NDType 2 Mellitus DiabetesMedDRA version: 13.1Level: LLTClassification code 10045242Term: Type II diabetes mellitusSystem Organ Class: 10027433 - Metabolism and nutrition disordersEUCTR2010-023231-42-ITELI LILLY260
